CN112618605B - 一种辅助降血脂的保健品 - Google Patents
一种辅助降血脂的保健品 Download PDFInfo
- Publication number
- CN112618605B CN112618605B CN202011350708.1A CN202011350708A CN112618605B CN 112618605 B CN112618605 B CN 112618605B CN 202011350708 A CN202011350708 A CN 202011350708A CN 112618605 B CN112618605 B CN 112618605B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- water
- parts
- vitamin
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 50
- 239000008280 blood Substances 0.000 title claims abstract description 50
- 230000036541 health Effects 0.000 title claims abstract description 22
- 229940088594 vitamin Drugs 0.000 claims abstract description 31
- 229930003231 vitamin Natural products 0.000 claims abstract description 31
- 235000013343 vitamin Nutrition 0.000 claims abstract description 31
- 239000011782 vitamin Substances 0.000 claims abstract description 31
- 150000002224 folic acids Chemical class 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 239000000047 product Substances 0.000 claims description 39
- 241000218236 Cannabis Species 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 26
- 238000005406 washing Methods 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 20
- 238000001179 sorption measurement Methods 0.000 claims description 20
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 19
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 18
- 239000011724 folic acid Substances 0.000 claims description 18
- 229960000304 folic acid Drugs 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 13
- 241001106477 Paeoniaceae Species 0.000 claims description 13
- 235000006533 astragalus Nutrition 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 229930003451 Vitamin B1 Natural products 0.000 claims description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- 229960003495 thiamine Drugs 0.000 claims description 10
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 10
- 235000019163 vitamin B12 Nutrition 0.000 claims description 10
- 239000011715 vitamin B12 Substances 0.000 claims description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims description 10
- 239000011726 vitamin B6 Substances 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 229940011671 vitamin b6 Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- -1 folic acid compound Chemical class 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 8
- 235000008191 folinic acid Nutrition 0.000 claims description 8
- 239000011672 folinic acid Substances 0.000 claims description 8
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 8
- 229960001691 leucovorin Drugs 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 229940065207 methylfolic acid Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 18
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 4
- 229940107666 astragalus root Drugs 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000010254 Jasminum officinale Nutrition 0.000 description 3
- 240000005385 Jasminum sambac Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健品技术领域,具体涉及一种辅助降血脂的保健品。所述辅助降血脂的保健品,包括如下组分:白芍、叶酸类化合物、金银花、火麻仁、黄芪、维生素。该产品副作用小、成本低,对辅助治疗高血脂症具有很好的效果。同时,制备方法简单,有利用推广应用。
Description
技术领域
本发明属于保健品技术领域,具体涉及一种辅助降血脂的保健品。
背景技术
血脂是血浆的中性脂肪和类脂物质的总称,主要成分有甘油三脂、总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇等。血液中一种或几种脂质水平升高(HDL-C降低),含量超过正常值,就叫做高脂血症,简称高血脂。高血脂是指血浆中的胆固醇、甘油三脂、磷脂和未脂化的脂酸等血脂成分增高的一种疾症。血脂过多,造成“血稠”,在血管壁沉积,形成小斑块(常说的“动脉粥样硬化”),这些“斑块”增多、增大,逐渐堵塞血管,使血流变慢,严重时血流被中断,引起冠心病、脑中风、视力下降、失明、肾动脉硬化,肾功能衰竭、肢体坏死、溃烂等疾病。
目前,临床上的降脂药物主要是:他汀类、贝特类、烟酸类、胆酸螯合剂和不饱和脂肪酸类等。但这些药物都有不同程度的胃肠反应、恶心、便秘或腹泻、头痛头晕、肝损伤等副作用。因此,研究开发辅助降血脂的保健食品,对于缓解高血脂引起的心脑血管疾病,保证人们的健康具有重大意义。
目前用于治疗高血脂病的药物分为西药和中药两种,但是现有的用于治疗高血脂病的西药副作用大,不能长期服用,且西药制作工艺复杂,所使用原料价格贵,得到的西药制剂价格偏高,而且用于治疗高血脂病的中药疗效不显著,药效差。
中药中众多研究成果,虽然起到了较好的作用,但仍然需要进一步改进。如中国专利申请CN 106551401 A公开了一种降血压降血脂葛根咀嚼片,由以下原料制成:新鲜葛根、梨皮、茉莉花、川芎、莪术、茯神、牛蒡、草莓、叶酸、硬脂酸镁、木耳多糖、花青素、芥菜、甘蔗汁。于携带,呈粉红色、有光泽、组织细腻、口感微甜爽滑、咀嚼效果好、带有淡淡的茉莉花香。本品适合易于吸收利用,无副作用,对高血压高血脂的人群有显著的治疗效果;加入的多种成分共同配合作用,能够有效消除疲劳,提高神经系统的兴奋性,降低工作人员的困乏,提高工作效率,促进新陈代谢和血液循环,增强人体抗病能力。虽然其优势众多,但该配方中组分种类较多,制备方法复杂,不利于降低成本。
又如中国专利申请CN102038745B公开了一种降血脂中药,按千粒量的重量计,取红曲150~220g,丹参2500~3300g,灵芝4800~5600g,并依次按下述步骤进行:a.丹参用乙醇加热回流浸提两次,提取液合并浓缩至稀膏状;b.将灵芝粉碎,加水煎煮2次,煎液合并滤过;c.将(a)和(b)步的药渣合并,加适量水煎煮,煎液过滤并与(b)步滤液合并,再浓缩至稀膏状;d.将(a)和(c)步的稀膏状物合并,加入红曲细粉和适量辅料制成颗粒,或制成胶囊或片剂。通过临床比较证明,本发明辅助降血脂中药在降低高胆固醇和高甘油三脂血症方面效果明显,并优于现有技术中的辅助降血脂产品。该发明虽具有较好的疗效,但其使用了灵芝这种昂贵药材,并不适于推广应用。
因此,有必要研究一种效果好,制备方法简单,成本低的辅助降血脂的产品。
发明内容
为克服以上技术问题,本发明提供了一种辅助降血脂的保健品。该产品效果好,制备方法简单,成本低,有利用推广应用。
为实现以上目的,本发明提供的技术方案如下:
一种辅助降血脂的保健品,包括如下组分:白芍、叶酸类化合物、金银花、火麻仁、黄芪、维生素。
优选地,按照重量份数计,所述辅助降血脂的保健品,包括如下组分:白芍5-20份、叶酸类化合物5-15份、金银花 5-15份、火麻仁 6-20份、黄芪 5-18份、维生素 1-5份。
优选地,按照重量份数计,所述辅助降血脂的保健品,包括如下组分:白芍10-20份、叶酸类化合物5-10份、金银花 5-8份、火麻仁 6-12份、黄芪 5-7份、维生素 3-5份。
优选地,所述维生素为维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。
优选地,所述维生素为质量比为1-3:1-2:1:1:1的维生素 C、维生素 B1、维生素B2、维生素 B6和维生素 B12的混合物。
优选地,所述叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐、叶酸或叶酸可药用盐的活性代谢产物和可在体内代谢和/或生成叶酸的物质中的一种或几种。
本发明的另一目的在于提供所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入乙醇浸泡,加热回流提取,浓缩,制得初步浓缩提取液;
(2)将初步浓缩提取液加入热水,搅拌,取上清液经大孔树脂柱吸附,得吸附柱;
(3)用水洗涤吸附柱两次,弃水洗液,再用乙醇洗脱,收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
优选地,步骤(1)中,所述乙醇为质量分数为65-85%的乙醇水溶液;
优选地,步骤(1)中,所述乙醇的加入量为白芍、金银花、火麻仁和黄芪总质量的10-15倍;
优选地,步骤(1)中,所述浸泡的时间为20-30min;
优选地,步骤(1)中,所述加热回流提取的次数为2-3次;每次提取1-3h。
优选地,步骤(1)中,所述初步浓缩提取液的体积为白芍、金银花、火麻仁和黄芪原料总质量的3-5倍;
优选地,步骤(2)中,所述热水的体积为初步浓缩提取液体积的3-5倍。
优选地,步骤(2)中,所述热水的温度为60-80℃。
优选地,步骤(2)中,所述大孔树脂柱为AB-8型大孔吸附树脂或X-5大孔吸附树脂。
优选地,步骤(3)中,所述用水洗涤的加水量为1-5 BV;优选为5 BV。
优选地,步骤(3)中,所述用水洗涤的流速为0.5-2.5 BV/h。
优选地,步骤(3)中,所述乙醇为质量分数为50-70%的乙醇水溶液。
优选地,步骤(3)中,所述乙醇的用量为3-5 BV。
优选地,步骤(3)中,所述乙醇洗脱时的流速为0.5-2.5 BV/h。
优选地,步骤(3)中,所述过筛的孔径为80-100目。
与现有技术比,本发明的技术优势在于:
(1)本发明提供的辅助降血脂的保健品副作用小、成本低,对治疗高血脂症具有很好的效果。
(2)本发明提供的辅助降血脂的保健品可以减轻肝肾负担,具有增强人体抵抗力的作用,还有平肝益气、活血调经、降脂减肥、补血柔肝、益精润燥、活血化淤及扩张血管功效。
(3)本发明的提取物中含有较多的芍药苷,在特定的比例下,叶酸中含有的羧基和氨基,与芍药苷中的羟基相互作用,有利于发挥混合提取物的辅助降血脂药效。
具体实施方式
下面通过具体实施例对本发明进行说明,以使本发明技术方案更易于理解、掌握,但本发明并不局限于此。下述实施例中所述实验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
实施例1
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍10份、叶酸类化合物10份、金银花 8份、火麻仁 12份、黄芪 7份、维生素 3份。
所述维生素为质量比为3:2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为甲酰四氢叶酸。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入12倍质量的75%的乙醇浸泡25min,加热回流提取2次,每次提取2h,合并提取液,浓缩至体积为白芍、金银花、火麻仁和黄芪原料总质量的4倍;制得初步浓缩提取液;
(2)将初步浓缩提取液加入4倍体积70℃的热水,搅拌,取上清液经AB-8型大孔吸附树脂吸附,得吸附柱;
(3)用3 BV的水洗涤吸附柱两次,控制流速为2 BV/h,弃水洗液,再用3 BV 的60%乙醇洗脱,控制流速为2BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过80目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
实施例2
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍5份、叶酸类化合物15份、金银花 5份、火麻仁 20份、黄芪 5份、维生素 1份。
所述维生素为质量比为1:1:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入10倍质量的65%的乙醇浸泡30min,加热回流提取3次,每次提取1h,合并提取液,浓缩至体积为白芍、金银花、火麻仁和黄芪原料总质量的3倍;制得初步浓缩提取液;
(2)将初步浓缩提取液加入5倍体积60℃的热水,搅拌,取上清液经X-5大孔吸附树脂吸附,得吸附柱;
(3)用1 BV的水洗涤吸附柱两次,控制流速为0.5 BV/h,弃水洗液,再用3 BV 的50%乙醇洗脱,控制流速为0.5 BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过100目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
实施例3
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍20份、叶酸类化合物5份、金银花 15份、火麻仁 6份、黄芪 18份、维生素 5份。
所述维生素为质量比为2:1:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为L-甲基叶酸。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入15倍质量的85%的乙醇浸泡20min,加热回流提取2次,每次提取3h,合并提取液,浓缩至体积为白芍、金银花、火麻仁和黄芪原料总质量的5倍;制得初步浓缩提取液;
(2)将初步浓缩提取液加入3倍体积80℃的热水,搅拌,取上清液经AB-8型大孔吸附树脂吸附,得吸附柱;
(3)用5 BV的水洗涤吸附柱两次,控制流速为2.5 BV/h,弃水洗液,再用5 BV 的70%乙醇洗脱,控制流速为2.5 BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过80目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
对比例1
与实施例1相比,区别在于组分不同。
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍10份、叶酸类化合物10份、金银花 8份、火麻仁 12份、白术 7份、维生素 3份。
所述维生素为质量比为3:2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为甲酰四氢叶酸。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和白术混合,加入12倍质量的75%的乙醇浸泡25min,加热回流提取2次,每次提取2h,合并提取液,浓缩至体积为白芍、金银花、火麻仁和白术原料总质量的4倍;制得初步浓缩提取液;
(2)将初步浓缩提取液加入4倍体积70℃的热水,搅拌,取上清液经AB-8型大孔吸附树脂吸附,得吸附柱;
(3)用3 BV的水洗涤吸附柱两次,控制流速为2 BV/h,弃水洗液,再用3 BV 的60%乙醇洗脱,控制流速为2BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过80目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
对比例2
与实施例1相比,区别在于组分不同。
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍10份、叶酸类化合物10份、蒲公英 8份、火麻仁 12份、黄芪 7份、维生素 3份。
所述维生素为质量比为3:2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为甲酰四氢叶酸。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、蒲公英、火麻仁和黄芪混合,加入12倍质量的75%的乙醇浸泡25min,加热回流提取2次,每次提取2h,合并提取液,浓缩至体积为白芍、蒲公英、火麻仁和黄芪原料总质量的4倍;制得初步浓缩提取液;
(2)将初步浓缩提取液加入4倍体积70℃的热水,搅拌,取上清液经AB-8型大孔吸附树脂吸附,得吸附柱;
(3)用3 BV的水洗涤吸附柱两次,控制流速为2 BV/h,弃水洗液,再用3 BV 的60%乙醇洗脱,控制流速为2BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过80目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
对比例3
与实施例1相比,区别在于组成配比不同。
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍30份、叶酸类化合物1份、金银花 8份、火麻仁 12份、黄芪 7份、维生素 3份。
所述维生素为质量比为3:2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为甲酰四氢叶酸。
所述辅助降血脂的保健品的制备方法,步骤同实施例1。
对比例4
与实施例1相比,区别在于组成配比不同。
一种辅助降血脂的保健品,按照重量份数计,包括如下组分:
白芍1份、叶酸类化合物25份、金银花 8份、火麻仁 12份、黄芪 7份、维生素 3份。
所述维生素为质量比为3:2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物。所述叶酸类化合物为甲酰四氢叶酸。
所述辅助降血脂的保健品的制备方法,步骤同实施例1。
对比例5
与实施例1相比,区别在于制备方法不同
一种辅助降血脂的保健品,组分同实施例1。
所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)将白芍、金银花、火麻仁、黄芪分别提取:
分别取白芍、金银花、火麻仁、黄芪加入12倍质量的75%的乙醇浸泡25min,加热回流提取2次,每次提取2h,分别浓缩至体积为原白芍、金银花、火麻仁、黄芪质量的4倍;分别制得白芍、金银花、火麻仁、黄芪的初步浓缩提取液;
(2)将白芍、金银花、火麻仁、黄芪的初步浓缩提取液混合后,加入4倍体积70℃的热水,搅拌,取上清液经AB-8型大孔吸附树脂吸附,得吸附柱;
(3)用3 BV的水洗涤吸附柱两次,控制流速为2 BV/h,弃水洗液,再用3 BV 的60%乙醇洗脱,控制流速为2BV/h收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过80目筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可。
效果例-辅助降血脂功能试验
试验方法:
选择健康成年雄性SD种大鼠(180g±5g)90只,按照高脂对照组和实施例1-3对比例1-5随机分成9组,每组10只。喂食高脂饲料(组成:78.8%基础饲料、1%胆固醇、10%蛋黄粉和10%猪油、0.2%胆盐。)建立高脂模型;再给予高脂饲料的同时进行预防性给受试样品30天。实验组和对比例组按照0.5mg/g BW灌胃对应实施例1-3对比例1-5组相应产品,高脂对照组每日按照0.5mg/g BW灌胃0.9%的生理盐水。实验结束后禁食16h,取尾血,测得小鼠血清总胆固醇(TC),甘油三酯(TG),高密度脂蛋白胆固醇(HDL-C)水平,结果见表1。
表1辅助降血脂功能试验结果
试验组 | TG(mmol/L) | TC(mmol/L) | HDL-C(mmol/L) |
高脂模型组 | 0.98±0.12 <sup>a</sup> | 4.26±0.92 <sup>d </sup> | 0.93±0.25<sup> m</sup> |
实施例1 | 0.61±0.09 <sup>b</sup> | 3.31±0.21<sup> e</sup> | 1.54±0.11<sup> n</sup> |
实施例2 | 0.63±0.17 <sup>b</sup> | 3.43±0.19<sup> e</sup> | 1.57±0.32<sup> n</sup> |
实施例3 | 0.62±0.21 <sup>b</sup> | 3.36±0.28<sup> e</sup> | 1.55±0.09<sup> n</sup> |
对比例1 | 0.79±0.13<sup> c</sup> | 3.52±0.34<sup> e</sup> | 1.44±0.18<sup> x</sup> |
对比例2 | 0.67±0.09<sup> b</sup> | 3.76±0.62<sup> f</sup> | 1.31±0.33<sup> x</sup> |
对比例3 | 0.72±0.22<sup> c</sup> | 3.91±0.57 <sup>f</sup> | 1.37±0.14<sup> x</sup> |
对比例4 | 0.68±0.31 <sup>b</sup> | 3.67±0.18<sup> f</sup> | 1.26±0.26 <sup>y</sup> |
对比例5 | 0.83±0.16<sup> c</sup> | 3.99±0.22<sup> f</sup> | 1.18±0.17<sup> y</sup> |
注:每一列不同字母之间代表具有显著性差异P<0.05
由此可知,本发明提供的实施例1-3的产品具有降低小鼠血清TG、TC和提高HDL-C含量的作用,可以改善血脂和脂蛋白水平,同时,产品组分和制备方法对其效果具有较大的影响。
上述详细说明是针对本发明其中之一可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明所为的等效实施或变更,均应包含于本发明技术方案的范围内。
Claims (5)
1.一种辅助降血脂的保健品,按照重量份数计,所述辅助降血脂的保健品,由如下组分制成:白芍10-20份、叶酸类化合物5-10份、金银花 5-8份、火麻仁 6-12份、黄芪 5-7份和维生素 3-5份;
所述维生素为质量比为1-3:1-2:1:1:1的维生素 C、维生素 B1、维生素 B2、维生素 B6和维生素 B12的混合物;所述叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐中的一种或几种;
其中,所述辅助降血脂的保健品的制备方法,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入乙醇浸泡,加热回流提取,浓缩,制得初步浓缩提取液;
(2)将初步浓缩提取液加入热水,搅拌,取上清液经大孔树脂柱吸附,得吸附柱;所述大孔树脂的型号为AB-8或X-5;
(3)用水洗涤吸附柱两次,弃水洗液,再用乙醇洗脱,收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可;
步骤(1)中,所述乙醇为质量分数为65-85%的乙醇水溶液;所述乙醇的加入量为白芍、金银花、火麻仁和黄芪总质量的10-15倍;所述浸泡的时间为20-30min;所述加热回流提取的次数为2-3次;每次提取1-3h;
步骤(3)中,所述用水洗涤的加水量为1-5 BV;所述用水洗涤的流速为0.5-2.5 BV/h;
步骤(3)中,所述乙醇为质量分数为50-70%的乙醇水溶液;所述乙醇的用量为3-5 BV;所述乙醇洗脱时的流速为0.5-2.5 BV/h;所述过筛的孔径为80-100目。
2.如权利要求1所述的辅助降血脂的保健品的制备方法,其特征在于,包括以下步骤:
(1)取白芍、金银花、火麻仁和黄芪混合,加入乙醇浸泡,加热回流提取,浓缩,制得初步浓缩提取液;
(2)将初步浓缩提取液加入热水,搅拌,取上清液经大孔树脂柱吸附,得吸附柱;所述大孔树脂的型号为AB-8或X-5;
(3)用水洗涤吸附柱两次,弃水洗液,再用乙醇洗脱,收集乙醇洗脱液,浓缩、干燥,制得混合提取物,粉碎过筛,制得混合提取物粉末;
(4)加入叶酸类化合物、维生素,混合均匀,即可;
步骤(1)中,所述乙醇为质量分数为65-85%的乙醇水溶液;所述乙醇的加入量为白芍、金银花、火麻仁和黄芪总质量的10-15倍;所述浸泡的时间为20-30min;所述加热回流提取的次数为2-3次;每次提取1-3h;
步骤(3)中,所述用水洗涤的加水量为1-5 BV;所述用水洗涤的流速为0.5-2.5 BV/h;
步骤(3)中,所述乙醇为质量分数为50-70%的乙醇水溶液;所述乙醇的用量为3-5 BV;所述乙醇洗脱时的流速为0.5-2.5 BV/h;所述过筛的孔径为80-100目。
3.如权利要求2所述的辅助降血脂的保健品的制备方法,其特征在于,步骤(1)中,所述初步浓缩提取液的体积为白芍、金银花、火麻仁和黄芪原料总质量的3-5倍。
4.如权利要求2所述的辅助降血脂的保健品的制备方法,其特征在于,步骤(2)中,所述热水的体积为初步浓缩提取液体积的3-5倍;所述热水的温度为60-80℃。
5.如权利要求2所述的辅助降血脂的保健品的制备方法,其特征在于,步骤(3)中,所述用水洗涤的加水量为5 BV。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011350708.1A CN112618605B (zh) | 2020-11-26 | 2020-11-26 | 一种辅助降血脂的保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011350708.1A CN112618605B (zh) | 2020-11-26 | 2020-11-26 | 一种辅助降血脂的保健品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112618605A CN112618605A (zh) | 2021-04-09 |
CN112618605B true CN112618605B (zh) | 2022-09-27 |
Family
ID=75304096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011350708.1A Active CN112618605B (zh) | 2020-11-26 | 2020-11-26 | 一种辅助降血脂的保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112618605B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103341120A (zh) * | 2013-06-13 | 2013-10-09 | 蒋俊安 | 一种纯中草药压降制剂 |
CN104106807A (zh) * | 2014-07-31 | 2014-10-22 | 赵兰 | 一种降血脂保健食品及其制备方法 |
CN105935392A (zh) * | 2016-06-24 | 2016-09-14 | 哈尔滨医科大学 | 一种用于治疗高脂血症的中药组合物及其制备方法和用途 |
CN109316565A (zh) * | 2018-11-19 | 2019-02-12 | 建昌帮药业有限公司 | 一种降血脂组合物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108686007A (zh) * | 2018-08-28 | 2018-10-23 | 深圳市必发达科技有限公司 | 一种降血脂的中药组合物 |
-
2020
- 2020-11-26 CN CN202011350708.1A patent/CN112618605B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103341120A (zh) * | 2013-06-13 | 2013-10-09 | 蒋俊安 | 一种纯中草药压降制剂 |
CN104106807A (zh) * | 2014-07-31 | 2014-10-22 | 赵兰 | 一种降血脂保健食品及其制备方法 |
CN105935392A (zh) * | 2016-06-24 | 2016-09-14 | 哈尔滨医科大学 | 一种用于治疗高脂血症的中药组合物及其制备方法和用途 |
CN109316565A (zh) * | 2018-11-19 | 2019-02-12 | 建昌帮药业有限公司 | 一种降血脂组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112618605A (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101513437B (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN101810793B (zh) | 玉米须黄酮在制备治疗高血脂症药物中的应用 | |
CN102423352B (zh) | 一种治疗心脑血管疾病的中药颗粒剂的制备方法 | |
CN103705594B (zh) | 治疗高脂血症的中药组合物及其制备方法 | |
CN108057039A (zh) | 一种铁皮石斛多糖和黄精多糖组合物及其制备方法与应用 | |
CN1222298C (zh) | 一种治疗心血管病的药物 | |
CN100469377C (zh) | 一种治疗前列腺炎的软胶囊 | |
CN112618605B (zh) | 一种辅助降血脂的保健品 | |
CN1557382A (zh) | 一种甙类化合物制剂及制备方法 | |
CN1695730A (zh) | 一种治疗高血脂症的中药组合物及其制备方法 | |
CN1288168C (zh) | 一种多糖类化合物制剂及制备方法 | |
CN1369289A (zh) | 治疗心脑血管疾病的中药制剂及其制作方法 | |
CN115475199A (zh) | 一种中药复方补血颗粒及其制备方法 | |
CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
CN101537054A (zh) | 一种能清血柔脉、强心护脑、调节血脂血压的制剂及其制备方法 | |
CN111000969A (zh) | 一种治疗单纯性肥胖的药物组合物及制备方法 | |
CN110664905A (zh) | 一种用于祛风散寒的中药制剂及其制备方法 | |
CN113170890B (zh) | 一种减脂抗糖的保健食品组合物及其制备方法 | |
CN115969903B (zh) | 一种中药组合物及其制备方法与在制备具有防治脂肪肝作用的药物中的应用 | |
CN1096218A (zh) | 一种治疗久泻久痢的中成药及其生产方法 | |
CN113425806B (zh) | 治疗心脑血管疾病的茶色素组合物及制备方法 | |
CN108186773A (zh) | 一种减肥降脂药物制剂及其制备方法 | |
CN115671211B (zh) | 一种参竹精片剂及其制备方法 | |
CN101167796B (zh) | 一种防治心脑血管疾病的红曲和丹参组合物 | |
CN116350715A (zh) | 一种治疗乳腺癌的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |